Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV000782222 | SCV002541506 | uncertain significance | not provided | 2022-01-13 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003456142 | SCV004177512 | uncertain significance | CFHR5 deficiency | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000782222 | SCV005847540 | uncertain significance | not provided | 2024-08-07 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln399*) in the CFHR5 gene. It is expected to result in an absent or disrupted protein product. However, the current clinical and genetic evidence is not sufficient to establish whether loss-of-function variants in CFHR5 cause disease. This variant is present in population databases (rs772780646, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with CFHR5-related conditions. ClinVar contains an entry for this variant (Variation ID: 632092). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gharavi Laboratory, |
RCV000782222 | SCV000920709 | uncertain significance | not provided | 2018-09-16 | no assertion criteria provided | research |